3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Pancreatic Neoplasms
36
Colorectal Neoplasms
17
Small Cell Lung Carcinoma
8
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Rhabdomyosarcoma
4
Recurrence
4
Osteosarcoma
4
Biliary Tract Neoplasms
4
Rectal Neoplasms
3
Ovarian Neoplasms
3
Cholangiocarcinoma
3
Triple Negative Breast Neoplasms
2
Solid Tumor
2
Neuroblastoma
2
Nasopharyngeal Carcinoma
2
Metastatic Pancreatic Adenocarcinoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Wilms Tumor
1
Weight Loss
1
Somatostatinoma
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Interventions
Gemcitabine
6
Fluorouracil
5
Leucovorin
4
Irinotecan
3
Albumin-Bound Paclitaxel
3
pembrolizumab
2
irinotecan sucrosofate
2
Oxaliplatin
2
4-fluorobenzoyl-TN-14003
2
zolbetuximab
1
regorafenib
1
olaparib
1
ibrutinib
1
beta-D-glucosylisophosphoramide mustard
1
adavosertib
1
Tetrahydrouridine
1
Telemedicine
1
Taxes
1
Practice Guidelines as Topic
1
Paclitaxel
1
PEGPH20
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Decitabine
1
Counseling
1
Cisplatin
1
Capecitabine
1
BKT140
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Pancreatic Adenocarcinoma
×
irinotecan sucrosofate
×
Clear all
NCT05383352
2025-04-30
SIRACUSA
Ipsen
Phase 1
Completed
177 enrolled
NCT02826486
2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2
Completed
80 enrolled
13 charts